BTK Inhibitors
6 drugsAbout BTK
Bruton's tyrosine kinase (BTK) is a tyrosine kinase enzyme crucial for cell signaling pathways in immune cell development and function. As a non-receptor tyrosine kinase, BTK is essential for B-cell receptor signaling and downstream activation of pathways. Its role in immune cell function makes it a valuable target for therapeutic intervention.
Human genetic studies provide strong validation for BTK as a therapeutic target, with a max genetic score of 0.95. Loss-of-function variants are associated with X-linked agammaglobulinemia (score 0.95) and isolated growth hormone deficiency (score 0.94), suggesting activation of BTK may be beneficial.
BTK is targeted by five FDA-approved small molecule drugs, including IMBRUVICA, CALQUENCE and JAYPIRCA. These drugs are used in oncology (2 drugs) and other therapeutic areas (3 drugs). Approvals span from IMBRUVICA in 2013 to RHAPSIDO in 2025.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 80% attractiveness score.
Human Genetic Evidence Strong
BTK has strong genetic support with a maximum score of 0.95 linked to X-linked agammaglobulinemia.
Strong genetic support suggests that therapies activating BTK have a higher probability of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in nervous system disease, endocrine system disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
8 totalGWAS and other genetic studies link BTK to 8 diseases.
Loss-of-function causes disease; activation may help
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Five companies have approved BTK-targeting drugs, including PHARMACYCLICS LLC, AstraZeneca and Novartis.
The presence of multiple companies suggests a competitive market, but also established pathways for regulatory approval.
Drug Modality Landscape
Modalities
Routes of Administration
BTK is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules indicates a potential whitespace opportunity for alternative modalities like antibodies.
Clinical Trials 539 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 195 | 105 | 35 | 55 | 75% |
| Phase 2 | 245 | 80 | 32 | 133 | 71% |
| Phase 3 | 87 | 29 | 5 | 53 | 85% |
| Phase 4 | 12 | 5 | 1 | 6 | 83% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved BTK drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BTK. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2013 - 2025)
BTK has seen approvals spanning 13 years, from 2013 to 2025.
The recent approval of RHAPSIDO in 2025 indicates continued interest and potential for further drug development targeting BTK.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 461 clinical trials targeting BTK.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities